Bio-Techne (TECH): FMR LLC now owns 5% of TECH as a passive investor 5.0%
FMR LLC now owns 5% of TECH as a passive investor.
- 5.0%
- Stake
- 7.86M
- Shares owned
- Stake as of
- Mar 31, 2026
- Filed
- May 6, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 28, 2026CongressDisclosed partial sale of TECH — reported range $1,001 - $15,000
- Feb 4, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
- Feb 9, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.”
- Feb 17, 2026InsiderDirector sold ~$117K of TECH shares in the open market
- Feb 24, 2026CongressDisclosed partial sale of TECH — reported range $1,001 - $15,000
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Mar 26, 2026CongressDisclosed partial sale of TECH — reported range $1,001 - $15,000
What came next
- Apr 8, 2026CongressDisclosed sale of TECH — reported range $1,001 - $15,000
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.4%
- May 6, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
- May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 5.0%
- May 8, 2026InsiderDirector sold ~$320K of TECH shares in the open market
- Jun 23, 2026Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement“On June 23, 2026, in connection with the contemplated Merger, the Compensation Committee of the Board (the “ Compensation Committee ”) approved cash retention bonus awards to each of the Company’s current named executive officers pursuant to retention agreements (the “ Retention Agreements ”) in order to encourage the Company’s named executive officers to remain with the Company and motivate their continued strong…”
How to read SEC Schedule 13G
A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.
Full guide: Schedule 13D vs Schedule 13G: what is the difference?
What else is on file for Bio-Techne
For Bio-Techne, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TECH page.
How this filing works
Explore the data
Common questions
What does this filing report about Bio-Techne (TECH) stock?
FMR LLC now owns 5% of TECH as a passive investor. Of the company, Schedule 13G (passive).
When did it happen, and when was it made public?
Stake as of: Mar 31, 2026. Filed: May 6, 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Bio-Techne recently?
For Bio-Techne, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the TECH page.
Does this mean TECH stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Bio-Techne
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRNov 13, 2026
- SEC Schedule 13GNov 5, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its TECH page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
